CliffBio
small molecule

DDAVP

DESMOPRESSIN ACETATE

Loss of exclusivity—loss of exclusivity
CompanyFerring Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameDDAVP
Active ingredientDESMOPRESSIN ACETATE
Strength0.1MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 1995
Marketing statusRX

More from Ferring Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DDAVP patent cliff — loss of exclusivity — | CliffBio